Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Inovio Pharmaceuticals Inc (INO) vs Veeva Systems (VEEV) Price & Performance

Inovio Pharmaceuticals IncTrade
Veeva SystemsTrade

Price performance (Past 24H)

Key statistics

Inovio Pharmaceuticals Inc vs Veeva Systems — how do they compare? Inovio Pharmaceuticals Inc trades at $1.12 (market cap $112.19M), while Veeva Systems trades at $295.82 (market cap $46.12B). The key difference: Veeva Systems is far larger — about 411.1× Inovio Pharmaceuticals Inc's market cap, and Veeva Systems is trading nearer its 52-week high, Inovio Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Inovio Pharmaceuticals Inc for 43 Days and Veeva Systems for 6 Days on average.

INOVEEV
Market Cap
$112.19M$46.12B
Volume
3,201,278921,537
Sector
HealthTechnology
52-Week High
$2.65$299.10
52-Week Low
$0.66$151.43
Typical Hold Time
43 Days6 Days
Enterprise Value
$83.51M$39.03B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Inovio Pharmaceuticals Inc

Inovio Pharmaceuticals (INO) trades at $1.09, down 5.63% today, reflecting ongoing financial challenges with minimal revenue of $65,340 in 2025 and substantial losses. The company shows consistent negative cash flow from operations but has beaten EPS estimates in recent quarters. Technical indicators are bearish, with moving averages and oscillators signaling selling pressure. Key near-term catalyst is the FDA's October 30, 2026 PDUFA date for INO-3107, its lead candidate for recurrent respiratory papillomatosis.

The investment case hinges on FDA approval of INO-3107, with analyst consensus target at $2.75 offering significant upside. However, high burn rate, negative margins, and dependence on financing pose substantial risks. Positive regulatory outcome could drive revaluation, but failure may exacerbate financial strain. Wall Street maintains cautious optimism with 59% buy ratings.

Veeva Systems

No Aura AI signal available yet.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

INO
96% Buy4% Sell
Avg holding period · 43 Days
VEEV

No sentiment data available yet.

Top news

Latest headlines on both assets

About Inovio Pharmaceuticals Inc

Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.

Read more on INO →

About Veeva Systems

Veeva Systems provides cloud software, data, and services for the life sciences industry. Its applications support functions across clinical research, regulatory operations, quality, safety, and commercial teams.

Read more on VEEV →